Skip to main content
ALK inhibitor alectinib shows DFS benefit in early NSCLC
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
ALK inhibitor alectinib shows DFS benefit in early NSCLC
User login
Username
Password
Reset your password
Concept
Lead
score
Non-Small Cell Lung Cancer
1
1
Lung Cancer
0
1
Chemotherapy
0
0.72
ALK Inhibitor
0
0.64
Anaplastic Lymphoma Kinase
0
0.9
Head and Neck Cancer
0
0.28
Adjuvant Setting
0
0.21
Toxicology
0
0.19
Lung Metastases
0
0.17
Metastasis
0
0.17
Small Cell Lung Cancer
0
0.15
Cancer
0
0.14
Platinum
0
0.14
Brain Metastasis
0
0.13
Adverse Effects
0
0.07
Brain
0
0.07
Central Nervous System
0
0.07
Disease Recurrence
0
0.07
Europe
0
0.07
Intravenous
0
0.07
Lung
0
0.07
Lymphoma
0
0.07
Medical Oncology
0
0.07
Muscle
0
0.07
Neuropathy
0
0.07
Quality of Life
0
0.07
Surgery
0
0.07
Constipation
0
0.06
Patient Safety
0
0.06
Specialty
Lead
score
Hematology-Oncology
1
1
Pharmacist
0
1
Pulmonary Medicine
0
1
Neurology & Neurosurgery
0
0.4
Gastroenterology
0
0.35
Family Medicine/Primary Care
0
0.34
Internal Medicine
0
0.31
Public Health & Prevention
0
0.21
General Surgery
0
0.13
Emergency Medicine
0
0.12
Edit Tags